Researchers determined patients with PNH demonstrated poorer HRQoL and greater functional impairment than observed in the general population.

Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase ...

Aortic stenosis, a narrowing of the aortic valve, is one of the most common and severe structural issues, particularly in ...

The following is a summary of "Supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States," published in the February 2025 issue of the Respiratory ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

Inc. , today announced a definitive merger agreement under which Bristol Myers Squibb ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash ...

dyspnea and viral infections. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do – TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating ...

A recent study from the Women’s Guild Lung Institute at Cedars-Sinai suggests that zinc could help reverse lung damage in ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.